Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBLIVAC FIX Birch Immunotherapy in Birch Pollen Allergic Rhinitis
NCT02231307Phase 3Completed
- Sponsor
- HAL Allergy Group
- Start
- Sep 2014
- Primary completion
- Jul 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
A Phase 3 trial of Sublivac Birch in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), sponsored by HAL Allergy Group. Started Sep 2014; status: completed.
02
Drugs
Sublivac Birch
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT02231307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231307.